This Article Full Text Full Text (PDF) All Versions of this Article: 1055-9965.EPI-07-0761v1 1055-9965.EPI-07-0761v2 17/3/614    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Rock, C. L. PubMed PubMed Citation Articles by Rock, C. L.

Reproductive Steroid Hormones and Recurrence-Free Survival in Women with a History of Breast Cancer

¹ Moores UCSD Cancer Center, University of California-San Diego, La Jolla, California; ² Department of Public Health Sciences, University of California-Davis, Davis, California; ³ Arizona Cancer Center, University of Arizona, Tucson, Arizona; ⁴ University of Texas M. D. Anderson Cancer Center, Houston, Texas; ⁵ Division of Research, Kaiser Permanente Northern California, Oakland, California; ⁶ Stanford Comprehensive Cancer Center, Stanford University, Stanford, California; and ⁷ Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, California

Requests for reprints: Cheryl L. Rock, Cancer Prevention and Control Program, Moores UCSD Cancer Center, University of California-San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0901. Phone: 858-822-1126; Fax: 858-822-6166. E-mail: clrock{at}ucsd.edu

Epidemiologic studies fairly consistently show in postmenopausal women that reproductive steroid hormones contribute to primary breast cancer risk, and this association is strongly supported by experimental studies using laboratory animals and model systems. Evidence linking sex hormone concentrations with risk for recurrence in women diagnosed with breast cancer is limited; however, beneficial effects of antiestrogenic therapy on recurrence-free survival suggest that these hormones affect progression and risk for recurrence. This study examined whether baseline serum concentrations of estradiol, testosterone, and sex hormone binding globulin were associated with recurrence-free survival in a nested case-control cohort of women from a randomized diet trial (Women's Healthy Eating and Living Study) who were followed for >7 years after diagnosis. In 153 case-control pairs of perimenopausal and postmenopausal women in this analysis, total estradiol [hazard ratio (HR), 1.41 per unit increase in log concentration; 95% confidence interval (95% CI), 1.01-1.97], bioavailable estradiol (HR, 1.26; 95% CI, 1.03-1.53), and free estradiol (HR, 1.31; 95% CI, 1.03-1.65) concentrations were significantly associated with risk for recurrence. Recurred women had an average total estradiol concentration that was double that of nonrecurred women (22.7 versus 10.8 pg/mL; P = 0.05). Testosterone and sex hormone binding globulin concentrations did not differ between cases and controls and were not associated with risk for recurrence. Although genetic and metabolic factors likely modulate the relationship between circulating sex hormones and risk, results from this study provide evidence that higher serum estrogen concentration contributes to risk for recurrence in women diagnosed with early stage breast cancer. (Cancer Epidemiol Biomarkers Prev 2008;17(3):614–20)